Research & Development
ASC Therapeutics Joins US Consortium of Gene Therapy Partners Including the NIH and FDA to Accelerate Treatments for Rare Diseases
26 May 2022 - - US-based biopharmaceutical company ASC Therapeutics has joined as a full partner the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC) including the National Institutes of Health and the Food and Drug Administration, managed by the Foundation for the National Institutes of Health, the company said.

The AMP BGTC brings together partners from the public, private, and non-profit sectors to foster development of gene therapies intended to treat rare genetic diseases, which affect populations too small for viable commercial development.

ASC Therapeutics is a biopharmaceutical company pioneering the development of gene replacement therapies, in-vivo gene editing and allogeneic cell therapies for hematological, metabolic, and other rare diseases.

The Accelerating Medicines Partnership program is a public-private partnership between the National Institutes of Health, the US Food and Drug Administration, and multiple public and private organizations.

The AMP BGTC aims to develop platforms and standards that will speed the development and delivery of customized or 'bespoke' gene therapies that could treat the ms of people affected by rare diseases.

The FNIH creates and manages alliances with public and private institutions in support of the mission of the NIH. The FNIH works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe.

Established by Congress in 1990, the FNIH is a not-for-profit 501(c) (3) charitable organization.


Related Headlines